ANTI-SCARRING

GENE THERAPY

The future is here

TECHNOLOGY

SCARRING
- A GLOBAL UNMET NEED

THE PROBLEM

Severe ("hypertrophic") dermal scars can be a stigma,

a burden or even a physical handicap

with reduced mobility of joints.

After burn injuries they are seen

in 70% to 90% of patients

and are recognized as

the predominant unmet need,

often resulting in life-long suffering.

Severe dermal scars are also reported

after surgery in up to one third of Caucasians and

two thirds of Chinese and Polynesians.

Other indications:

Scarring and adhesions in body cavities after

hip or knee replacement
back surgery (spinal laminctomy)
abdominal surgery
gynecological surgery

OUR INNOVATION

Cellastra is pioneering a potentially revolutionary treatment: CELLEXA

A gene vector delivering the genetic code to enable robust continuous production of an antiscarring peptide edirectly in the wound to promote scar less wound healing.

Get In Touch

CLX-003

CLX-003 is a formulation for injection after after back surgery (spinal laminectomy) or for prevention of intrabdominal adhesions after abdominal or gynecological surgery.

HOW DOES IT WORK?

CELLLEXA is a formulation of an effective transport vehicle (viral vector)
It is programmed with the genetic code for natural lactoferrin derived anti-scarring peptides.
Applied on top of he skin or by injection CELLEXA delivers the code to the cell factory
It activates the continuous production for many months of anti-scarring peptides in the cells of the wound area.

THE PEPTIDES DISRUPTS ROOT CAUSES OF SCARRING

CELLEXA (CLX-001)

CLX-001 is gene therapy to prevent scarring after burn injury..

Applied topically by spray or ointment suitable for larger body surface area.

CLX-002

CXL-002 for prevention of dermal scarring after surgery. Applied as gel before wound closure or injected subcuteneously into the wound area in cosmetically challening areas such as the face, mammoplasty or after C-section..